Organovo Holdings Inc Stock Research

Market Summary

USD1.98+0.07

Delayed

3.66%

ONVO Stock Price

ONVO RSI Chart

ONVO Valuation

Market Cap

17.3M

Price/Earnings (Trailing)

-1.47

Price/Sales (Trailing)

58.56

Price/Free Cashflow

-1.8

ONVO Price/Sales (Trailing)

ONVO Profitability

Return on Equity

-52.54%

Return on Assets

-46.7%

Free Cashflow Yield

-55.49%

ONVO Fundamentals

ONVO Revenue

Revenue Y/Y

-82.53%

Revenue Q/Q

70.13%

ONVO Earnings

Earnings (TTM)

-11.7M

Earnings Y/Y

6.74%

Earnings Q/Q

1.72%

Price Action

52 Week Range

1.374.11

(Low)(High)

Last 7 days

-8.6%

Last 30 days

-10.3%

Last 90 days

7.3%

Trailing 12 Months

-50.1%

ONVO Financial Health

Current Ratio

15.71

ONVO Investor Care

Shares Dilution (1Y)

0.10%

Diluted EPS (TTM)

-1.34

Peers (Alternatives to Organovo Holdings)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
GILD	99.6B	27.3B	-8.96%	41.01%	21.68	3.65	-0.09%	-26.23%
MRNA	58.4B	19.3B	-12.76%	1.00%	6.99	3.03	4.29%	-31.47%
INCY	16.5B	3.4B	-9.50%	-1.15%	48.37	4.85	13.67%	-64.09%
EXAS	11.8B	2.1B	-1.61%	11.81%	-18.88	5.65	17.95%	-4.68%
MID-CAP
EXEL	5.7B	1.6B	0.62%	-12.32%	31.44	3.56	12.27%	-21.11%
DNLI	3.2B	108.5M	-21.10%	-19.55%	-9.78	29.38	122.90%	-12.19%
IMVT	2.0B	-	-14.81%	192.41%	-9.94	-	-	-44.28%
SMALL-CAP
IOVA	1.2B	-	-5.15%	-45.48%	-3.14	-	-	-15.67%
ADMA	615.9M	130.5M	-14.48%	101.94%	-8.76	4.72	90.44%	5.49%
NVAX	513.7M	2.0B	-39.67%	-92.01%	-0.78	0.26	72.89%	62.27%
ORGO	276.2M	450.9M	-22.02%	-71.01%	17.79	0.61	-3.52%	-83.51%
SRNE	143.9M	60.3M	-71.28%	-88.95%	-0.29	2.39	17.51%	-38.93%
PBYI	98.8M	228.0M	-44.24%	-11.03%	49.4K	0.43	-9.92%	100.01%
ENOB	56.8M	-	0.97%	-84.15%	-0.52	-	-	-182.89%
ONVO	17.3M	-	-10.33%	-50.13%	-1.47	58.56	-83.33%	3.48%

Financials for Organovo Holdings

* denotes actual numbers (not divided by Thousands)
Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q1	2021Q4	2020Q1
Revenue	NaN%			1,500	1,848	2,196
Operating Expenses	-0.1%	13,547	13,560	12,755	-	-
S&GA Expenses	-2.9%	9,002	9,271	9,659	9,306	-
R&D Expenses	6.0%	4,571	4,312	3,320	2,858	-
Costs and Expenses	-	12,979	-	-	-	-
EBITDA	-	-2.90	-	-	-	-
EBITDA Margin	-	0.00*	-	-	-	-
EBT Margin	-	-0.06*	-	-	-	-
Net Income	2.0%	-11,711	-11,947	-11,448	-12,133	-
Net Income Margin	-408.2%	-38.79*	-7.63*	-	-	-
Free Cahsflow	3.5%	-9,575	-9,923	-8,862	-	-

* denotes actual numbers (not divided by Thousands)
Balance Sheet					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-10.1%	25,079	27,910	30,546	33,296	35,095
Current Assets	-11.3%	21,614	24,357	26,909	29,533	31,171
Cash Equivalents	52.3%	20,200	13,265	15,568	28,675	30,269
Net PPE	-2.1%	742	758	690	662	652
Liabilities	-3.9%	2,790	2,904	2,892	3,087	3,802
Current Liabilities	-0.9%	1,376	1,389	1,282	1,383	2,006
Shareholder's Equity	-10.9%	22,289	25,006	27,654	30,209	31,293
Retained Earnings	-1.0%	-317,539	-314,300	-310,954	-307,739	-305,800
Additional Paid-In Capital	0.2%	339,817	339,273	338,600	337,940	337,113
Accumulated Depreciation	-	1,071	-	-	-	-
Shares Outstanding	0.0%	8,715	8,713	8,712	8,711	8,706

* denotes actual numbers (not divided by Thousands)
Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	2.7%	-9,288	-9,544	-9,487	-8,500	-9,026
Share Based Compensation	-1.6%	2,704	2,748	2,501	2,256	1,716
Cashflow From Investing	92.2%	-857	-10,965	-10,908	-409	-467
Cashflow From Financing	100.0%	0.00	-1.00	-46.00	205	20,958
Buy Backs	NaN%	0.00	0.00	-	-	-

Risks for ONVO

What is the probability of a big loss on ONVO?

100%

Probability that Organovo Holdings stock will be more than 20% underwater in next one year

100%

Probability that Organovo Holdings stock will be more than 30% underwater in next one year.

99.6%

Probability that Organovo Holdings stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ONVO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Organovo Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for ONVO

Cumulative Returns on ONVO

-31.0%

10-Year Cumulative Returns

-36.2%

7-Year Cumulative Returns

-38.7%

5-Year Cumulative Returns

-26.7%

3-Year Cumulative Returns

What are the long-term rolling returns for ONVO?

FIve years rolling returns for Organovo Holdings.

Annualized Returns

Which funds bought or sold ONVO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-06	Rockefeller Capital Management L.P.	new	-	-	-	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	unchanged	-	173	173	-%
2023-02-15	Steward Partners Investment Advisory, LLC	unchanged	-	7.00	7.00	-%
2023-02-15	Virtu Financial LLC	sold off	-100	-30,000	-	-%
2023-02-14	ROYAL BANK OF CANADA	sold off	-100	-	-	-%
2023-02-14	MILLENNIUM MANAGEMENT LLC	sold off	-100	-50,000	-	-%
2023-02-14	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	0.73	-31,046	71,954	-%
2023-02-14	NewEdge Advisors, LLC	new	-	15.00	15.00	-%
2023-02-14	FIRST MANHATTAN CO	unchanged	-	35.00	35.00	-%
2023-02-14	MORGAN STANLEY	reduced	-0.51	-22,523	47,477	-%

Latest Funds Activity

Are funds buying ONVO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ONVO

No. of Funds

Organovo Holdings News

Schedule 13G FIlings of Organovo Holdings

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 03, 2023	sumitomo mitsui trust holdings, inc.	5.21%	454,752	SC 13G/A
Feb 14, 2022	nikko asset management americas, inc.	5.50%	478,570	SC 13G/A
Feb 04, 2022	sumitomo mitsui trust holdings, inc.	5.49%	478,570	SC 13G/A
Mar 10, 2021	ark investment management llc	9.48%	674,454	SC 13G/A
Feb 16, 2021	ark investment management llc	20.86%	1,404,620	SC 13G/A
Feb 11, 2021	renaissance technologies llc	5.36%	381,353	SC 13G/A
Feb 11, 2021	nikko asset management americas, inc.	7.11%	478,570	SC 13G/A
Feb 05, 2021	sumitomo mitsui trust holdings, inc.	7.11%	478,570	SC 13G/A
Oct 09, 2020	ark investment management llc	21.78%	1,422,394	SC 13G/A
Feb 14, 2020	ark investment management llc	14.95%	19,499,439	SC 13G/A

ONVO Fair Value

Recent SEC filings of Organovo Holdings

View All Filings

Date Filed	Form Type	Document
Mar 15, 2023	8-K	Current Report
Feb 10, 2023	SC 13G/A	Major Ownership Report
Feb 09, 2023	10-Q	Quarterly Report
Feb 03, 2023	SC 13G/A	Major Ownership Report

Latest Insider Trading transactions for ONVO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-11-10	Joshi Vaidehi	acquired	-	-	19,607	-
2022-11-10	Gobel David	acquired	-	-	19,607	-
2022-11-10	Milhous Alison Tjosvold	acquired	-	-	19,607	-
2022-11-10	Cohen Douglas Jay	acquired	-	-	19,607	-
2022-11-10	STERN ADAM K	acquired	-	-	19,607	-
2022-11-10	Murphy Keith	acquired	-	-	19,607	executive chairman
2021-11-19	Gobel David	sold	-766	5.285	-145	-
2021-08-17	Cohen Douglas Jay	bought	6,719	6.7198	1,000	-
2021-08-17	Cohen Douglas Jay	bought	58,838	6.7244	8,750	-
2021-08-17	Cohen Douglas Jay	bought	6,737	6.7379	1,000	-

About Organovo Holdings

Keith Murphy

www.organovo.com

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

ONVO Income Statement

2022-09-30

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues
Total Revenues	$ 77	$ 0	$ 77	$ 0
Revenue From Contract With Customer Product And Service [Extensible List]	us-gaap:RoyaltyMember	us-gaap:RoyaltyMember	us-gaap:RoyaltyMember	us-gaap:RoyaltyMember
Research and development expenses	$ 1,231	$ 679	$ 2,251	$ 1,259
Selling, general and administrative expenses	2,200	2,828	4,419	4,807
Total costs and expenses	3,431	3,507	6,670	6,066
Loss from Operations	(3,354)	(3,507)	(6,593)	(6,066)
Other Income (Expense)
Loss on investment in equity securities	(70)	0	(75)	0
Interest income	103	2	134	4
Other income	0	0	0	25
Total Other Income	33	2	59	29
Income Tax Expense	0	0	(2)	0
Net Loss	$ (3,321)	$ (3,505)	$ (6,536)	$ (6,037)
Net loss per common share basic	$ (0.38)	$ (0.40)	$ (0.75)	$ (0.69)
Net loss per common share diluted	$ (0.38)	$ (0.40)	$ (0.75)	$ (0.69)
Weighted average shares used in computing net loss per common share basic	8,712,284	8,705,327	8,711,630	8,701,029
Weighted average shares used in computing net loss per common share diluted	8,712,284	8,705,327	8,711,630	8,701,029
Comprehensive Loss:
Net loss	$ (3,321)	$ (3,505)	$ (6,536)	$ (6,037)
Comprehensive loss	$ (3,321)	$ (3,505)	$ (6,536)	$ (6,037)

ONVO Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Current Assets
Cash and cash equivalents	$ 13,265	$ 28,675
Short-term investments	9,955	0
Investment in equity securities	618	0
Prepaid expenses and other current assets	519	858
Total current assets	24,357	29,533
Fixed assets, net	758	662
Restricted cash	143	143
Operating lease right-of-use assets	1,958	2,153
Prepaid expenses and other assets, net	694	805
Total assets	27,910	33,296
Current Liabilities
Accounts payable	441	415
Accrued expenses	462	489
Operating lease liability, current portion	486	479
Total current liabilities	1,389	1,383
Operating lease liability, net of current portion	1,515	1,704
Total liabilities	2,904	3,087
Stockholders’ Equity
Common stock, $0.001 par value; 200,000,000 shares authorized, 8,713,268 and 8,710,627 shares issued and outstanding at September 30, 2022 and March 31, 2022, respectively	9	9
Additional paid-in capital	339,273	337,940
Accumulated deficit	(314,275)	(307,739)
Treasury stock, 46 shares at cost	(1)	(1)
Total stockholders’ equity	25,006	30,209
Total Liabilities and Stockholders’ Equity	$ 27,910	$ 33,296